Anti-Fibrinolytic Drugs - Israel

Israel

The Anti-Fibrinolytic Drugs market in Israel is expected to generate a revenue of US$49.31m in 2024.
It is projected to exhibit a compound annual growth rate (CAGR 2024-2029) of 4.73%, leading to a market volume of US$62.14m by 2029.
When compared globally, United States is anticipated to generate the highest revenue, amounting to US$9,858.00m in 2024.
Israel is experiencing a surge in the demand for anti-fibrinolytic drugs, driven by the country's advanced healthcare system and high prevalence of cardiovascular diseases.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

Anti-Fibrinolytic Drugs are used to prevent the breakdown of blood clots in the body. In Israel, the market for these drugs has been developing in a certain way due to various factors.

Customer preferences: Israeli customers prefer drugs that are effective and have minimal side effects. They are willing to pay a premium price for drugs that meet these criteria. They also prefer drugs that are easily accessible and can be obtained without much hassle.

Trends in the market: The Anti-Fibrinolytic Drugs market in Israel has been growing steadily due to an increase in the prevalence of bleeding disorders. This has led to an increase in the demand for drugs that can prevent excessive bleeding. Another trend in the market is the development of new drugs that are more effective and have fewer side effects. These drugs are expected to drive the growth of the market in the coming years.

Local special circumstances: Israel has a well-developed healthcare system that provides universal coverage to its citizens. This has led to an increase in the demand for Anti-Fibrinolytic Drugs as more people have access to healthcare. Additionally, Israel has a high incidence of bleeding disorders such as hemophilia, which has further increased the demand for these drugs.

Underlying macroeconomic factors: Israel has a strong economy with a high GDP per capita. This has led to an increase in the purchasing power of its citizens, making it easier for them to afford expensive drugs. Additionally, Israel has a well-developed pharmaceutical industry that has been investing heavily in research and development. This has led to the development of new drugs that are more effective and have fewer side effects, further driving the growth of the Anti-Fibrinolytic Drugs market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.